• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    RLX Technology Extends US$500 Million Share Repurchase Program

    12/31/25 3:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $RLX alert in real time by email

    SHENZHEN, China, Dec. 31, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that its board of directors has authorized the extension of its existing share repurchase program for an additional 24-month period through December 31, 2027. The existing share repurchase program was established in December 2021 and extended in December 2023. Under the current share repurchase program, the Company may repurchase up to US$500 million of its ordinary shares represented by ADSs until December 31, 2025. As of December 31, 2025, the Company had cumulatively repurchased approximately 170 million ordinary shares represented by ADS for an aggregate amount of approximately US$330 million, with approximately US$170 million remaining unused. Under the extended share repurchase program, the Company may repurchase up to approximately US$170 million of the ADSs through December 31, 2027.

    The Company's proposed repurchases may be made from time to time on the open market at prevailing market prices, in privately negotiated transactions, in block trades, through structured or derivative transactions and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. The Company's board of directors will review the share repurchase program periodically, and may authorize adjustment of its terms and size. The Company expects to fund the repurchases out of its existing cash balance.

    About RLX Technology Inc.

    RLX Technology Inc. (NYSE:RLX) is a leading global branded e-vapor company. The Company leverages its strong in-house technology, product development capabilities, and in-depth insights into adult smokers' needs to develop superior e-vapor products.

    For more information, please visit: http://ir.relxtech.com.

    Safe Harbor Statement

    This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" and similar statements. Among other things, quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward- looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's growth strategies; its future business development, results of operations and financial condition; trends and competition in China's e-vapor market; changes in its revenues and certain cost or expense items; PRC governmental policies, laws and regulations relating to the Company's industry, and general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is current as of the date of this press release, and the Company does not undertake any obligation to update such information, except as required under applicable law.

    Cision View original content:https://www.prnewswire.com/news-releases/rlx-technology-extends-us500-million-share-repurchase-program-302650994.html

    SOURCE RLX Technology Inc.

    Get the next $RLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RLX

    DatePrice TargetRatingAnalyst
    3/17/2025$2.80 → $2.50Buy → Neutral
    Citigroup
    8/8/2023$2.60Buy
    UBS
    More analyst ratings

    $RLX
    SEC Filings

    View All

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    11/14/25 6:02:26 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    8/22/25 7:09:03 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    5/16/25 6:02:23 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $RLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RLX Technology Extends US$500 Million Share Repurchase Program

    SHENZHEN, China, Dec. 31, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that its board of directors has authorized the extension of its existing share repurchase program for an additional 24-month period through December 31, 2027. The existing share repurchase program was established in December 2021 and extended in December 2023. Under the current share repurchase program, the Company may repurchase up to US$500 million of its ordinary shares represented by ADSs until December 31, 2025. As of December 31, 2025, the Company had cumulatively repurchased approximately 170 million ordinary share

    12/31/25 3:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology Announces Unaudited Third Quarter 2025 Financial Results

    SHENZHEN, China, Nov. 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Net revenues were RMB1,129.3 million (US$158.6 million) in the third quarter of 2025, compared with RMB756.3 million in the same period of 2024.Gross margin was 31.2% in the third quarter of 2025, compared with 27.2% in the same period of 2024.Non-GAAP income from operations[1] was RMB187.8 million (US$26.4 million) in the third quarter of 2025, compared with RMB84.0 million in the same period of 2024.U

    11/14/25 4:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology to Report Third Quarter 2025 Financial Results on November 14, 2025

    - Earnings Call Scheduled for 7:00 a.m. ET on November 14, 2025 - SHENZHEN, China, Nov. 3, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2025, before the U.S. markets open on Friday, November 14, 2025. The Company's management will host an earnings conference call at 7:00 AM U.S. Eastern Time on November 14, 2025 (8:00 PM Beijing/Hong Kong Time on November 14, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-

    11/3/25 1:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology downgraded by Citigroup with a new price target

    Citigroup downgraded RLX Technology from Buy to Neutral and set a new price target of $2.50 from $2.80 previously

    3/17/25 7:42:34 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    UBS initiated coverage on RLX Technology with a new price target

    UBS initiated coverage of RLX Technology with a rating of Buy and set a new price target of $2.60

    8/8/23 9:12:45 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/7/24 6:06:29 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/6/24 4:01:28 PM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/14/23 6:01:42 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Financials

    Live finance-specific insights

    View All

    RLX Technology Announces Unaudited Third Quarter 2025 Financial Results

    SHENZHEN, China, Nov. 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Net revenues were RMB1,129.3 million (US$158.6 million) in the third quarter of 2025, compared with RMB756.3 million in the same period of 2024.Gross margin was 31.2% in the third quarter of 2025, compared with 27.2% in the same period of 2024.Non-GAAP income from operations[1] was RMB187.8 million (US$26.4 million) in the third quarter of 2025, compared with RMB84.0 million in the same period of 2024.U

    11/14/25 4:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology to Report Third Quarter 2025 Financial Results on November 14, 2025

    - Earnings Call Scheduled for 7:00 a.m. ET on November 14, 2025 - SHENZHEN, China, Nov. 3, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2025, before the U.S. markets open on Friday, November 14, 2025. The Company's management will host an earnings conference call at 7:00 AM U.S. Eastern Time on November 14, 2025 (8:00 PM Beijing/Hong Kong Time on November 14, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-

    11/3/25 1:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology Announces Unaudited Second Quarter 2025 Financial Results

    SHENZHEN, China, Aug. 22, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Net revenues were RMB880.0 million (US$122.8 million) in the second quarter of 2025, compared with RMB627.2 million in the same period of 2024.Gross margin was 27.5% in the second quarter of 2025, compared with 25.2% in the same period of 2024.Non-GAAP income from operations[1] was RMB116.2 million (US$16.2 million) in the second quarter of 2025, compared with RMB46.9 million in the same period of 2024.U.S

    8/22/25 5:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care